CD8A and ovarian cancer: According to Zhai et al., overexpression of MUC16 in ovarian cancer activates the PI3K/AKT pathway, promoting tumor cell proliferation and invasion while also enhancing anti-tumor immune responses, primarily manifested in dendritic cell maturation and CD8+ T cell activation (83).